Skip to content

Study · Randomized controlled trial · n = 1,620 · 2007

10 results

Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.

Dawson-Hughes B, Chen P, Krege JH

The Journal of clinical endocrinology and metabolism2 Oct 2007Cited by 19 (Europe PMC)

PMID17911178 (opens in a new tab)DOI10.1210/jc.2007-0239 (opens in a new tab)PepBankPUB-17911178
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced vertebral fracture risk versus placebo in both vitamin D status subgroups.

    In plain wordsTeriparatide reduced vertebral fracture risk versus placebo in women with insufficient or sufficient vitamin D.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fracture risk
    Study

    n = 1,620

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg daily · subcutaneous · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    3 context sentences
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced nonvertebral fracture risk versus placebo in both vitamin D status subgroups.

    In plain wordsTeriparatide reduced nonvertebral fracture risk versus placebo in women with insufficient or sufficient vitamin D.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNonvertebral fracture risk
    Study

    n = 1,620

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg daily · subcutaneous · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    3 context sentences
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased lumbar spine BMD versus placebo in both vitamin D status subgroups.

    In plain wordsTeriparatide increased spine bone density versus placebo in women with insufficient or sufficient vitamin D.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 1,620

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg daily · subcutaneous · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    3 context sentences
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased femoral neck BMD versus placebo in both vitamin D status subgroups.

    In plain wordsTeriparatide increased femoral neck bone density versus placebo in women with insufficient or sufficient vitamin D.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n = 1,620

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg daily · subcutaneous · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    3 context sentences
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased the bone formation marker versus placebo in both vitamin D status subgroups.

    In plain wordsTeriparatide increased the bone formation marker versus placebo in women with insufficient or sufficient vitamin D.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseProcollagen type 1 amino-terminal extension peptide
    Study

    n = 1,620

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg daily · subcutaneous · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    3 context sentences
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Vertebral fracture responses to teriparatide did not differ significantly by vitamin D subgroup, although limited fractures prevented excluding differences.

    In plain wordsVertebral fracture responses did not differ significantly between vitamin D subgroups, but limited fracture numbers prevented excluding differences.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVertebral fracture treatment response by vitamin D status
    Study

    n = 1,620

    Comparator
    Vitamin D insufficiency versus sufficiency
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10).
    5 context sentences
    Summary · context
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    Summary · context
    However, it should be noted that because of the limited number of fractures, this study does not exclude the possibility of differences in fracture outcome between the subgroups.
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Nonvertebral fracture responses to teriparatide did not differ significantly by vitamin D subgroup, although limited fractures prevented excluding differences.

    In plain wordsNonvertebral fracture responses did not differ significantly between vitamin D subgroups, but limited fracture numbers prevented excluding differences.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNonvertebral fracture treatment response by vitamin D status
    Study

    n = 1,620

    Comparator
    Vitamin D insufficiency versus sufficiency
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10).
    5 context sentences
    Summary · context
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    Summary · context
    However, it should be noted that because of the limited number of fractures, this study does not exclude the possibility of differences in fracture outcome between the subgroups.
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Lumbar spine BMD responses to teriparatide did not differ significantly between vitamin D subgroups.

    In plain wordsSpine bone density responses to teriparatide did not differ significantly between vitamin D subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine BMD response by vitamin D status
    Study

    n = 1,620

    Comparator
    Vitamin D insufficiency versus sufficiency
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10).
    4 context sentences
    Summary · context
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Femoral neck BMD responses to teriparatide did not differ significantly between vitamin D subgroups.

    In plain wordsFemoral neck bone density responses to teriparatide did not differ significantly between vitamin D subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFemoral neck BMD response by vitamin D status
    Study

    n = 1,620

    Comparator
    Vitamin D insufficiency versus sufficiency
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10).
    4 context sentences
    Summary · context
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Bone formation marker responses to teriparatide did not differ significantly between vitamin D subgroups.

    In plain wordsBone formation marker responses to teriparatide did not differ significantly between vitamin D subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone formation marker response by vitamin D status
    Study

    n = 1,620

    Comparator
    Vitamin D insufficiency versus sufficiency
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10).
    4 context sentences
    Summary · context
    TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups.
    Summary · context
    Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial.
    Summary · context
    The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but 30 but <or=183 ng/ml) at the baseline (randomization) visit.
    Summary · context
    At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.